IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J. Dore; Elizabeth Powell; Stephen Riordan; Antonina Smedile; Vincenzo Fragomeli; Tobias Muller; Melanie Bahlo; Graeme J. Stewart; David R. Booth; Jacob George

doi:10.1038/ng.447

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

Vijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, Thomas Berg, Martin Weltman, Maria Lorena Abate, Margaret Bassendine, Ulrich Spengler, Gregory J. Dore, Elizabeth Powell, Stephen Riordan, Antonina Smedile, Vincenzo Fragomeli, Tobias Muller, Melanie Bahlo, Graeme J. Stewart, David R. Booth, Jacob George

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-α/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFN3; rs8099917 combined P = 9.25 ÃÂ 10 9, OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.

Original language	English
Pages (from-to)	1100-1104
Number of pages	5
Journal	Nature Genetics
Volume	41
Issue number	10
DOIs	https://doi.org/10.1038/ng.447
Publication status	Published - 2009

Keywords

hepatitis C
interferon
interleukins
ribavirin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ng.447

Cite this

Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., Powell, E., Riordan, S., Smedile, A., Fragomeli, V., Muller, T., Bahlo, M., Stewart, G. J., Booth, D. R., & George, J. (2009). IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genetics, 41(10), 1100-1104. https://doi.org/10.1038/ng.447

@article{6299015f93cc4595989bbc46c1777b6f,

title = "IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy",

abstract = "Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-α/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFN3; rs8099917 combined P = 9.25 {\~A}{\^A} 10 9, OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.",

keywords = "hepatitis C, interferon, interleukins, ribavirin",

author = "Vijayaprakash Suppiah and Max Moldovan and Golo Ahlenstiel and Thomas Berg and Martin Weltman and Abate, {Maria Lorena} and Margaret Bassendine and Ulrich Spengler and Dore, {Gregory J.} and Elizabeth Powell and Stephen Riordan and Antonina Smedile and Vincenzo Fragomeli and Tobias Muller and Melanie Bahlo and Stewart, {Graeme J.} and Booth, {David R.} and Jacob George",

year = "2009",

doi = "10.1038/ng.447",

language = "English",

volume = "41",

pages = "1100--1104",

journal = "Nature Genetics",

issn = "1061-4036",

publisher = "Nature Publishing Group",

number = "10",

}

Suppiah, V, Moldovan, M, Ahlenstiel, G, Berg, T, Weltman, M, Abate, ML, Bassendine, M, Spengler, U, Dore, GJ, Powell, E, Riordan, S, Smedile, A, Fragomeli, V, Muller, T, Bahlo, M, Stewart, GJ, Booth, DR & George, J 2009, 'IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy', Nature Genetics, vol. 41, no. 10, pp. 1100-1104. https://doi.org/10.1038/ng.447

TY - JOUR

T1 - IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

AU - Suppiah, Vijayaprakash

AU - Moldovan, Max

AU - Ahlenstiel, Golo

AU - Berg, Thomas

AU - Weltman, Martin

AU - Abate, Maria Lorena

AU - Bassendine, Margaret

AU - Spengler, Ulrich

AU - Dore, Gregory J.

AU - Powell, Elizabeth

AU - Riordan, Stephen

AU - Smedile, Antonina

AU - Fragomeli, Vincenzo

AU - Muller, Tobias

AU - Bahlo, Melanie

AU - Stewart, Graeme J.

AU - Booth, David R.

AU - George, Jacob

PY - 2009

Y1 - 2009

N2 - Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-α/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFN3; rs8099917 combined P = 9.25 ÃÂ 10 9, OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.

AB - Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-α/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFN3; rs8099917 combined P = 9.25 ÃÂ 10 9, OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.

KW - hepatitis C

KW - interferon

KW - interleukins

KW - ribavirin

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:43992

U2 - 10.1038/ng.447

DO - 10.1038/ng.447

M3 - Article

SN - 1061-4036

VL - 41

SP - 1100

EP - 1104

JO - Nature Genetics

JF - Nature Genetics

IS - 10

ER -

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this